Generic · Injection
Valproate 100 mg/mL, 5 mL injection price what pharmacies pay, and what you should
There is no weekly pharmacy acquisition cost for valproate 100 mg/ml, 5 ml injection this week. The makers, package codes, recalls and label are below.
What people paid for valproate 100 mg/ml, 5 ml injection
What did your pharmacy charge? It takes 30 seconds, it's anonymous - and it shows everyone which pharmacies are fair.
Supply status: shortages & recalls
Shortages
- Valproate Sodium, Injection, 100 mg/1 mL (NDC 63323-494-05)Next release November 2026. Check wholesalers for inventory.
- Valproate Sodium, Injection, 500 mg/5 mL (NDC 0143-9785-10)Additional lots will be available. Product will be made available as it is released.
In a shortage, ask your pharmacist whether another strength, form or maker is in stock, and how much notice they need. What to do in a drug shortage.
Recalls
Showing the 6 most relevant of 10 - all recalls.
A recall names specific lots. Check the lot number on your package against the recall before you worry - and don't stop a medicine without asking your pharmacist. What to do if your medication is recalled.
Every manufacturer and package code
3 companies sell valproate 100 mg/ml, 5 ml injection under 5 package codes (NDCs).
| Maker | Package codes | Per unit |
|---|---|---|
| Fresenius Kabi USA, LLC | 63323-494-05 63323-494-16 | - |
| Hikma Pharmaceuticals USA Inc. | 0143-9637-10 0143-9785-10 | - |
| Sagent Pharmaceuticals | 25021-797-05 | - |
All 5 package codes
A dash means no weekly price for that maker's packages. Which maker your pharmacy stocks usually doesn't change what you pay, but you can ask.
Other valproate strengths and forms
| Strength and form | Per unit | Pharmacies pay |
|---|---|---|
| 250 mg capsule | $0.2422 | $7.27 / 30 capsules |
| 125 mg delayed-release capsule | $0.1971 | $5.91 / 30 capsules |
| 125 mg delayed-release tablet | $0.0532 | $1.60 / 30 tablets |
| 250 mg delayed-release tablet | $0.0847 | $2.54 / 30 tablets |
| 500 mg delayed-release tablet | $0.1561 | $4.68 / 30 tablets |
| 250 mg (24 hr) extended-release tablet | $0.1386 | $4.16 / 30 tablets |
| 500 mg (24 hr) extended-release tablet | $0.1957 | $5.87 / 30 tablets |
| 50 mg/mL oral solution | $0.0335 | $6.71 / 200 mL |
Official label & what changed
These highlights do not include all the information needed to use DIVALPROEX SODIUM DELAYED-RELEASE TABLETS safely and effectively. See full prescribing information for DIVALPROEX SODIUM DELAYED-RELEASE TABLETS. DIVALPROEX SODIUM delayed-release tablets, for oral use Initial U.S. Approval: 1983
WARNING: LIFE THREATENING ADVERSE REACTIONS
WARNING: LIFE THREATENING ADVERSE REACTIONS
See full prescribing information for complete boxed warning.
Hepatotoxicity, including fatalities, usually during the first 6 months of treatment. Children under the age of two years and patients with mitochondrial disorders are at higher risk. Monitor patients closely, and perform serum liver testing prior to therapy and at frequent intervals thereafter (
5.1)
Fetal Risk, particularly neural tube defects, other major malformations, and decreased IQ (
5.2,
5.3,
5.4)
Pancreatitis, including fatal hemorrhagic cases (
5.5)
Hepatotoxicity
General Population:Hepatic failure resulting in fatalities has occurred in patients receiving valproate and its derivatives. These incidents usually have occurred during the first six months of treatment. Serious or fatal hepatotoxicity may be preceded by non-specific symptoms such as malaise, weakness, lethargy, facial edema, anorexia, and vomiting. In patients with epilepsy, a loss of seizure control may also occur. Patients should be monitored closely for appearance of these symptoms. Serum liver tests should be performed prior to therapy and at frequent intervals thereafter, especially during the first six months
[see
Warnings and Precautions (5.1)]
.
Children under the age of two years are at a considerably increased risk of developing fatal hepatotoxicity, especially those on multiple anticonvulsants, those with congenital metabolic disorders, those with severe seizure disorders accompanied by mental retardation, and those with organic brain disease. When divalproex sodium delayed-release tablets are used in this patient group, it should be used with extreme caution and as a sole agent. The benefits of therapy should be weighed against the risks. The incidence of fatal hepatotoxicity decreases considerably in progressively older patient groups.
Patients with Mitochondrial Disease:There is an increased risk of valproate-induced acute liver failure and resultant deaths in patients with hereditary neurometabolic syndromes caused by DNA mutations of the mitochondrial DNA Polymerase
γ
(POLG) gene (e.g. Alpers-Huttenlocher Syndrome). Divalproex sodium delayed-release tablets are contraindicated in patients known to have mitochondrial disorders caused by POLG mutations and children under two years of age who are clinically suspected of having a mitochondrial disorder
[see
Contraindications (4)]
. In patients over two years of age who are clinically suspected of having a hereditary mitochondrial disease, divalproex sodium delayed-release tablets should only be used after other anticonvulsants have failed. This older group of patients should be closely monitored during treatment with divalproex sodium delayed-release tablets for the development of acute liver injury with regular clinical assessments and serum liver testing. POLG mutation screening should be performed in accordance with current clinical practice
[see
Warnings and Precautions (5.1)]
.
Fetal Risk
Valproate can cause major congenital malformations, particularly neural tube defects (e.g., spina bifida). In addition, valproate can cause decreased IQ scores and neurodevelopmental disorders following
in uteroexposure.
Valproate is therefore contraindicated for prophylaxis of migraine headaches in pregnant women and in women of childbearing potential who are not using effective contraception
[see
Contraindications (4)]
. Valproate should not be used to treat women with epilepsy or bipolar disorder who are pregnant or who plan to become pregnant unless other medications have failed to provide adequate symptom control or are otherwise unacceptable.
Valproate should not be administered to a woman of childbearing potential unless other medications have failed to provide adequate symptom control or are otherwise unacceptable. In such situations, effective contraception should be used
[see
Warnings and Precautions (5.2,
5.3,
5.4)]
.
A Medication Guide describing the risks of valproate is available for patients
[see
Patient Counseling Information (17)]
.
Pancreatitis
Cases of life-threatening pancreatitis have been reported in both children and adults receiving valproate. Some of the cases have been described as hemorrhagic with a rapid progression from initial symptoms to death. Cases have been reported shortly after initial use as well as after several years of use. Patients and guardians should be warned that abdominal pain, nausea, vomiting, and/or anorexia can be symptoms of pancreatitis that require prompt medical evaluation. If pancreatitis is diagnosed, valproate should ordinarily be discontinued. Alternative treatment for the underlying medical condition should be initiated as clinically indicated
[see
Warnings and Precautions (5.5)]
.
We check this label every day. When it changes, the sections that changed appear here, old text beside new.
We show the official text and what changed; we don't interpret it. Ask your pharmacist or prescriber what a change means for you.
Questions about valproate 100 mg/ml, 5 ml injection
Who makes valproate 100 mg/ml, 5 ml injection?
3 companies: Fresenius Kabi USA, LLC, Hikma Pharmaceuticals USA Inc., Sagent Pharmaceuticals. See every package code.
Is valproate in shortage?
Yes - 2 products are listed as short or being discontinued. Details.
Has valproate been recalled?
10 recalls on record, 1 ongoing. Recalls name specific lots - check yours.
What does "pharmacies pay" mean?
It's the national average price retail pharmacies pay wholesalers and makers to buy the drug, from a weekly government survey of pharmacy invoices. It doesn't include the pharmacy's costs of filling a prescription, which is why the fair price adds a margin and a dispensing fee. How we work it out.
Talk about valproate 100 mg/ml, 5 ml injection
No comments yet. Questions, tips, what worked for you - start the conversation.